Severe COVID-19 patients experience hyperactivation of immune responses, predominantly polyfunctionality in CD8+ T cells, distinct CD4+ T-cell subpopulations, and B-cell heterogeneity (41). This evidence concerns the gene CD8A and COVID-19.